CTOs on the Move

Phosplatin Therapeutics

www.phosplatin.com

 
Phosplatin Therapeutics is a private, clinical stage biopharmaceutical company founded in 2010, and funded by private investors and family investment offices in the U.S., Europe and Asia.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Phosplatin Therapeutics raised $16M on 10/31/2018
Phosplatin Therapeutics raised $18.4M on 08/26/2020

Similar Companies

Abengoa

Abengoa applies innovative technology solutions for sustainability in the energy and environment sectors, generating electricity from renewable resources, converting biomass into biofuels and producing drinking water from sea water. Abengoa’s business is structured around three activities.

Q-Chuck Technologies

Q-Chuck Technologies Inc. is a Edmonton, AB-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Exosome Diagnostics

Exosome Diagnostics is developing biofluid-based molecular diagnostic tests for use in personalized medicine. Exosomes and other microvesicles are shed into all biofluids, including blood, urine and cerebrospinal fluid, forming a highly enriched source of intact, disease-specific nucleic acids. The Company`s proprietary exosome technology makes use of this natural enrichment to achieve high sensitivity and specificity for rare gene transcripts and the expression of genes responsible for cancers and other diseases.

Kyn Therapeutics

Kyn Therapeutics is building a new generation of immuno-oncology therapies targeting powerful immunosuppressive metabolic networks. We envision a future where immunotherapies are the foundation of every cancer patient`s treatment, delivering rapid and durable responses. The Kyn team is composed of drug hunters, translational researchers and entrepreneurs drawn from many of the largest innovators in biotechnology supported by world-class advisors, and is backed by a seasoned board of directors anchored by OrbiMed Healthcare Fund Management and Atlas Venture. Kyn Therapeutics is headquartered in the biotech hub of Cambridge, Massachusetts.

Rgenix

Rgenix is a preclinical stage pharmaceutical company with a mission to develop the world`s first cancer therapies designed specifically to target cancer metastasis, the main cause of mortality in cancer patients. Rgenix is leading the revolution in next-generation cancer therapies with first-in-class lead drug candidates for several aggressive cancer subtypes, including Triple-Negative Breast Cancer, Melanoma and Colorectal Cancer.